OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers Research & Therapy is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
A novel electric field approach for improving cognitive function through ameliorating cell-specific pathology in P301S tauopathy mice	244
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	240
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	173
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	162
Association between antemortem plasma and structural MRI biomarkers and postmortem tau pathology in the Mayo Clinic Study of Aging	162
Associations of adherence to a healthy sleep pattern with the dementia risk in the UK biobank	159
Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease	139
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	126
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	122
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	121
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	119
Global and domain-specific cognitive intraindividual variability associations with neurodegenerative diagnoses and postmortem pathologies	111
Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis	104
Longitudinal evaluation of common and unique brain-networks in variants of primary progressive aphasia	104
Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine	96
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	93
Automated high-throughput quantification of plasma p-tau217 and APOE-ε4 for Alzheimer’s disease diagnosis and cognitive decline in a memory cohort	93
Diagnostic performance of verbal fluency measures: a cross-sectional study in the stages of cognitive continuum	93
Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology	87
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer’s disease	87
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	86
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	83
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	81
ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer’s disease	74
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	74

Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	72
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	69
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	65
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	64
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	64
Linking eye movements, pupil responses, and brain networks in early cognitive decline	64
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	63
Amyloid-β PET scans, economic strain and financial decision-making among persons with cognitive impairment and care partners: a mixed-methods analysis of the CARE-IDEAS study	61
Fluid biomarkers for neurodegenerative diseases: a comprehensive update	60
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	59
Meprin-β levels are increased in the brain and the cerebrospinal fluid of Alzheimer’s disease patients	57
The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors	56
Moderating role of executive function in the relationship between specific white matter changes and long-term delayed recall in aMCI patients	55
Structural brain improvements following individually tailored serious exergame-based training in mild neurocognitive disorders: exploratory randomized controlled trial	54
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	53
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	52
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	52
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	52
Reduced plasma TIA-1: bridging established pathology and novel biomarker potential	50
Real—world application of lecanemab in early—stage alzheimer's disease: a single—center prospective cohort analysis	48
Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline	48
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	46